Viridian Therapeutics, Inc. (VRDN) Tops Q3 EPS by 16c

Viridian Therapeutics, Inc. (NASDAQ: VRDN) reported Q3 EPS of ($1.09), $0.16 better than the analyst estimate of ($1.25). Revenue for the quarter came in at $72 thousand versus the consensus estimate of $141.08 thousand.

For earnings history and earnings-related data on Viridian Therapeutics, Inc. (VRDN) click here.

You May Also Be Interested In

• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• Bernstein SocGen Reiterates Outperform Rating on Fervo Energy (FRVO)
• Ennis (EBF) Reports In-Line Q1 EPS